Malaria vaccine study pulled before it began

NCT ID NCT07208760

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study was designed to see if giving a single dose of an antibody called L9LS changes how well the R21/Matrix-M malaria vaccine works. It planned to enroll healthy adults and infants in Mali. However, the trial was withdrawn before any participants were enrolled, so no data was collected.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

L9LS (a monoclonal antibody) and R21/Matrix-M malaria vaccine

What this could lead to

If successful, this could help design better malaria prevention strategies by understanding how antibodies and vaccines work together.

What could go wrong

The trial was withdrawn before enrolling anyone, so no results are available. It is unclear if the approach is safe or effective.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALARIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malaria prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Sotuba Malaria Research and Training Center (MRTC)

    Sotouba, Mali